Thrombotic microangiopathies (TMA) include a heterogeneous group of syndromes that share common pathological characteristics, or rather endothelial cellular damage and microvascular thrombosis, and a clinical triad characterized by thrombocytopenia, haemolytic anaemia and signs of ischemic suffering in various body areas, mainly, but not limited to kidney and central nervous system.1 TMA are: Pre-eclampsia/Eclampsia, HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), atypical haemolytic-uremic syndrome (a-HUS) and typical, disseminated intravascular coagulation (CID) and antiphospholipid antibody syndrome.